Scholarlink

<p>Contemporary small-molecule drug candidates increasingly have limited aqueous solubility, rendering oral delivery challenging. Amorphous solid dispersions (ASDs) and lipid-based formulations (LBFs) have evolved as leading formulation approaches to mitigate solubility and dissolution rate limitations. There is an increasing trend towards ASD formulations for drug candidates with high melting points and LBFs for extremely lipophilic molecules. Mechanistic assessment of LBF and ASD enhancement pathways reveals a surprising amount of commonality, notably that supersaturation generation and maintenance are likely key to obtaining optimized in vivo performance for both formulation types. An expanding formulation design space is blurring the distinction between these solubility enhancement technologies and further evolution in this direction is likely necessary to address the oral delivery of even more challenging molecules, such as proteolysis-targeting chimeras and macrocyclic peptides.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The expanding role of formulations to enable oral delivery of poorly water-soluble drugs

  • 期刊论文

  • 发表日期：

    2026年4月2日

查看全文
  • Keisuke Ueda,
  • Christopher J. H. Porter,
  • Aaron Goodwin,
  • Lynne S. Taylor

摘要

Contemporary small-molecule drug candidates increasingly have limited aqueous solubility, rendering oral delivery challenging. Amorphous solid dispersions (ASDs) and lipid-based formulations (LBFs) have evolved as leading formulation approaches to mitigate solubility and dissolution rate limitations. There is an increasing trend towards ASD formulations for drug candidates with high melting points and LBFs for extremely lipophilic molecules. Mechanistic assessment of LBF and ASD enhancement pathways reveals a surprising amount of commonality, notably that supersaturation generation and maintenance are likely key to obtaining optimized in vivo performance for both formulation types. An expanding formulation design space is blurring the distinction between these solubility enhancement technologies and further evolution in this direction is likely necessary to address the oral delivery of even more challenging molecules, such as proteolysis-targeting chimeras and macrocyclic peptides.